Portal de Periódicos da CAPES

Metastatic Gastrointestinal Stromal Tumor with an Exon 11 c-Kit Mutation Responding to the Tyrosine Kinase Inhibitor Imatinib

2004; Karger Publishers; Volume: 21; Issue: 1 Linguagem: Inglês

10.1159/000076756

1421-9883

Haruhiko Cho, Osamu Kobayashi, Akira Tsuburaya, Yuka Sugiyama, Motonori Sairenji, Hisahiko Motohashi, Tsutomu Yoshida, Yohei Miyagi, Toshio Imada,

Sarcoma Diagnosis and Treatment

Case Reports| April 08 2004 Metastatic Gastrointestinal Stromal Tumor with an Exon 11 c-Kit Mutation Responding to the Tyrosine Kinase Inhibitor Imatinib Subject Area: Gastroenterology , Surgery Haruhiko Cho; Haruhiko Cho aDepartments of Gastrointestinal Surgery and Search for other works by this author on: This Site PubMed Google Scholar Osamu Kobayashi; Osamu Kobayashi aDepartments of Gastrointestinal Surgery and Search for other works by this author on: This Site PubMed Google Scholar Akira Tsuburaya; Akira Tsuburaya aDepartments of Gastrointestinal Surgery and Search for other works by this author on: This Site PubMed Google Scholar Yuka Sugiyama; Yuka Sugiyama aDepartments of Gastrointestinal Surgery and Search for other works by this author on: This Site PubMed Google Scholar Motonori Sairenji; Motonori Sairenji aDepartments of Gastrointestinal Surgery and Search for other works by this author on: This Site PubMed Google Scholar Hisahiko Motohashi; Hisahiko Motohashi aDepartments of Gastrointestinal Surgery and Search for other works by this author on: This Site PubMed Google Scholar Tsutomu Yoshida; Tsutomu Yoshida bLaboratory for Molecular Diagnostics/Pathology Division, Kanagawa Cancer Center, and Search for other works by this author on: This Site PubMed Google Scholar Yohei Miyagi; Yohei Miyagi bLaboratory for Molecular Diagnostics/Pathology Division, Kanagawa Cancer Center, and Search for other works by this author on: This Site PubMed Google Scholar Toshio Imada Toshio Imada cMedical Center Gastroenterological Center, Yokohama City University, Yokohama, Japan Search for other works by this author on: This Site PubMed Google Scholar Dig Surg (2004) 21 (1): 74–77. https://doi.org/10.1159/000076756 Article history Received: September 27 2002 Accepted: July 15 2003 Published Online: April 08 2004 Content Tools Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Citation Haruhiko Cho, Osamu Kobayashi, Akira Tsuburaya, Yuka Sugiyama, Motonori Sairenji, Hisahiko Motohashi, Tsutomu Yoshida, Yohei Miyagi, Toshio Imada; Metastatic Gastrointestinal Stromal Tumor with an Exon 11 c-Kit Mutation Responding to the Tyrosine Kinase Inhibitor Imatinib. Dig Surg 1 July 2004; 21 (1): 74–77. https://doi.org/10.1159/000076756 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsDigestive Surgery Search Advanced Search Article PDF first page preview Close Modal This content is only available via PDF. 2004Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. You do not currently have access to this content.